Global Trastuzumab Biosimilars Supply, Demand and Key Producers, 2023-2029
The global Trastuzumab Biosimilars market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Trastuzumab is used for the treatment of HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.
This report studies the global Trastuzumab Biosimilars production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Trastuzumab Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Trastuzumab Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Trastuzumab Biosimilars total production and demand, 2018-2029, (K Units)
Global Trastuzumab Biosimilars total production value, 2018-2029, (USD Million)
Global Trastuzumab Biosimilars production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Trastuzumab Biosimilars consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Trastuzumab Biosimilars domestic production, consumption, key domestic manufacturers and share
Global Trastuzumab Biosimilars production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Trastuzumab Biosimilars production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Trastuzumab Biosimilars production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Trastuzumab Biosimilars market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fosun International Limited, Anhui Anke Bioengineering, Hisun Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Genentech Inc, Daiichi Sankyo, Pfizer, Celltrion Healthcare and Baxter Oncology GmbH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Trastuzumab Biosimilars market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Trastuzumab Biosimilars Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Trastuzumab Biosimilars Market, Segmentation by Type
Humanized Trastuzumab
Animal-derived Trastuzumab
Global Trastuzumab Biosimilars Market, Segmentation by Application
Hospital
Clinic
Companies Profiled:
Fosun International Limited
Anhui Anke Bioengineering
Hisun Biopharmaceuticals
Chia Tai Tianqing Pharmaceutical Group
Genentech Inc
Daiichi Sankyo
Pfizer
Celltrion Healthcare
Baxter Oncology GmbH
Sandoz
Key Questions Answered
1. How big is the global Trastuzumab Biosimilars market?
2. What is the demand of the global Trastuzumab Biosimilars market?
3. What is the year over year growth of the global Trastuzumab Biosimilars market?
4. What is the production and production value of the global Trastuzumab Biosimilars market?
5. Who are the key producers in the global Trastuzumab Biosimilars market?